{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:28:36Z","timestamp":1788791316211,"version":"build-2803163510"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone loss and bone metastases can increase morbidity and impair quality of life for patients with prostate cancer. Use of hormonal agents can compromise bone integrity from treatment initiation, and the emergence of bone metastases further increases the risk of symptomatic skeletal-related events. Management of bone health should therefore be pivotal across the prostate cancer continuum. Current guidelines recommend that all men starting or receiving androgen-deprivation therapy for prostate cancer be assessed regularly for bone loss using predictive tools such as dual-energy X-ray absorptiometry and Trabecular Bone Score. Bone health agents (BHAs) are recommended for all men with castration-resistant prostate cancer with skeletal metastases to prevent symptomatic skeletal-related events and for high-risk men receiving androgen-deprivation therapy to prevent treatment-related bone loss. Options include bisphosphonates such as zoledronic acid and alendronate and the receptor activator of nuclear factor kappa-B ligand inhibitor denosumab. Patients should be monitored for adverse effects of BHAs, such as osteonecrosis of the jaw and hypocalcemia. Alongside BHAs, there are treatment options for metastatic castration-resistant prostate cancer associated with beneficial bone-related effects, notably abiraterone acetate, enzalutamide, and radium-223. In this narrative review, we focus on how bone health management can be integrated into standard clinical practice in men with advanced prostate cancer. We also present a test-and-treatment algorithm for bone health management in men with metastatic prostate cancer. Improving treatment-related bone loss and proactively managing bone metastases should be standard practice in all men with prostate cancer to improve health outcomes and quality of life.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag321","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:21:08Z","timestamp":1787570468000},"source":"Crossref","is-referenced-by-count":0,"title":["Bone health in advanced prostate cancer: pathophysiology and management strategies"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R","family":"McKay","sequence":"first","affiliation":[{"name":"Department of Medicine and Urology, University of California San Diego , San Diego, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hofflich","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego , San Diego, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3028-6411","authenticated-orcid":false,"given":"Gina","family":"Woods","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego , San Diego, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Andres","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals , Whippany, NJ 07981,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeez","family":"Farooki","sequence":"additional","affiliation":[{"name":"Department of Medicine and Endocrinology, David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026090709460745700_oyag321-B1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.hoc.2013.08.009","article-title":"Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer","volume":"27","author":"McKay","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026090709460745700_oyag321-B2","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25 Suppl 3","author":"Coleman","year":"2014","journal-title":"Ann Oncol."},{"key":"2026090709460745700_oyag321-B3","doi-asserted-by":"publisher","first-page":"a033688","DOI":"10.1101\/cshperspect.a033688","article-title":"Metastases in prostate cancer","volume":"9","author":"La Manna","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026090709460745700_oyag321-B4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"2026090709460745700_oyag321-B5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"key":"2026090709460745700_oyag321-B6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","article-title":"Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"24","author":"Hussain","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026090709460745700_oyag321-B7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/ju.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"2026090709460745700_oyag321-B8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B9","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(10)61389-x","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"2026090709460745700_oyag321-B11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B15","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/s1470-2045(12)70473-4","article-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026090709460745700_oyag321-B16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s1470-2045(15)70113-0","article-title":"Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial","volume":"16","author":"Loriot","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026090709460745700_oyag321-B17","author":"NCCN (National Comprehensive Cancer Network)","year":"2026","journal-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer (Version 5.2026\u2014January 23, 2026)"},{"key":"2026090709460745700_oyag321-B18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41391-022-00573-y","article-title":"Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer","volume":"26","author":"Mitchell","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026090709460745700_oyag321-B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1200\/JCO.2025.43.5_suppl.95","article-title":"Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US","volume":"43","author":"Swami","year":"2025","journal-title":"JCO"},{"key":"2026090709460745700_oyag321-B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clgc.2021.10.008","article-title":"Symptomatic skeletal events and the use of bone health agents in a real-world treated metastatic castration resistant prostate cancer population: results from the CAPRI-study in The Netherlands","volume":"20","author":"Kuppen","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2026090709460745700_oyag321-B21","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.jbo.2018.100212","article-title":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2019","journal-title":"J Bone Oncol"},{"key":"2026090709460745700_oyag321-B22","author":"Organon LLC","year":"2026"},{"key":"2026090709460745700_oyag321-B23","author":"AbbVie","year":"2026"},{"key":"2026090709460745700_oyag321-B24","author":"Hikma Pharmaceuticals USA Inc","year":"2025"},{"key":"2026090709460745700_oyag321-B25","author":"Sandoz Inc","year":"2026"},{"key":"2026090709460745700_oyag321-B26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pros.24636","article-title":"Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer","volume":"84","author":"Mitchell","year":"2024","journal-title":"Prostate"},{"key":"2026090709460745700_oyag321-B27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00198-014-2997-6","article-title":"Bone health management in men undergoing ADT: examining enablers and barriers to care","volume":"26","author":"Damji","year":"2015","journal-title":"Osteoporos Int"},{"key":"2026090709460745700_oyag321-B28","doi-asserted-by":"publisher","first-page":"e13611","DOI":"10.1111\/ijcp.13611","article-title":"Use of bisphosphonates and other bone supportive agents in the management of prostate cancer-A UK perspective","volume":"74","author":"Payne","year":"2020","journal-title":"Int J Clin Pract"},{"key":"2026090709460745700_oyag321-B29","author":"Medicare.gov","year":"2026"},{"key":"2026090709460745700_oyag321-B30","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1677\/jme.0.0260079","article-title":"Osteoporosis, genetics and hormones","volume":"26","author":"Rizzoli","year":"2001","journal-title":"J Mol Endocrinol"},{"key":"2026090709460745700_oyag321-B32","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"2026090709460745700_oyag321-B33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3390\/cancers12061529","article-title":"Pathophysiology of bone loss in patients with prostate cancer receiving androgen-deprivation therapy and lifestyle modifications for the management of bone health: a comprehensive review","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers"},{"key":"2026090709460745700_oyag321-B34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/1756287216686018","article-title":"Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience","volume":"9","author":"Hegemann","year":"2017","journal-title":"Ther Adv Urol"},{"key":"2026090709460745700_oyag321-B35","doi-asserted-by":"publisher","first-page":"1127637","DOI":"10.3389\/fonc.2023.1127637","article-title":"The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"2026090709460745700_oyag321-B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eursup.2004.09.001","article-title":"Pathophysiology of bone metastases in prostate cancer","volume":"3","author":"Abrahamsson","year":"2004","journal-title":"Eur Urol Suppl"},{"key":"2026090709460745700_oyag321-B37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat Med"},{"key":"2026090709460745700_oyag321-B38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0022-5347(01)65196-6","article-title":"Correlation between bone metabolic markers and bone scan in prostatic cancer","volume":"157","author":"Maeda","year":"1997","journal-title":"J Urol"},{"key":"2026090709460745700_oyag321-B39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/bjc.1994.377","article-title":"Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis","volume":"70","author":"Sano","year":"1994","journal-title":"Br J Cancer"},{"key":"2026090709460745700_oyag321-B40","first-page":"917","article-title":"Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer","volume":"62","author":"Yi","year":"2002","journal-title":"Cancer Res"},{"key":"2026090709460745700_oyag321-B41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/bonekey.2015.85","article-title":"Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review","volume":"4","author":"Bienz","year":"2015","journal-title":"Bonekey Rep"},{"key":"2026090709460745700_oyag321-B42","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","article-title":"Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia","volume":"20","author":"Goebell","year":"2024","journal-title":"Future Oncol"},{"key":"2026090709460745700_oyag321-B43","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090709460745700_oyag321-B44","doi-asserted-by":"publisher","first-page":"104817","DOI":"10.1016\/j.ebiom.2023.104817","article-title":"Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial","volume":"97","author":"David","year":"2023","journal-title":"eBioMedicine"},{"key":"2026090709460745700_oyag321-B45","doi-asserted-by":"publisher","first-page":"115293","DOI":"10.1016\/j.ejca.2025.115293","article-title":"Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial","volume":"218","author":"Roubaud","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026090709460745700_oyag321-B46","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"key":"2026090709460745700_oyag321-B47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States","volume":"21","author":"Beebe-Dimmer","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026090709460745700_oyag321-B48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","article-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men","volume":"184","author":"Alibhai","year":"2010","journal-title":"J Urol"},{"key":"2026090709460745700_oyag321-B49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bju.12646","article-title":"Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial","volume":"115","author":"Cormie","year":"2015","journal-title":"BJU Int"},{"key":"2026090709460745700_oyag321-B50","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1249\/mss.0000000000000265","article-title":"Skeletal response to resistance and impact training in prostate cancer survivors","volume":"46","author":"Winters-Stone","year":"2014","journal-title":"Med Sci Sports Exerc"},{"key":"2026090709460745700_oyag321-B51","doi-asserted-by":"publisher","first-page":"R371","DOI":"10.1530\/erc-14-0172","article-title":"Muscle and bone effects of androgen deprivation therapy: current and emerging therapies","volume":"21","author":"Cheung","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2026090709460745700_oyag321-B52","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4008","article-title":"A comparison of bone-targeted exercise strategies to reduce fracture risk in middle-aged and older men with osteopenia and osteoporosis: LIFTMOR-M semi-randomized controlled trial","volume":"35","author":"Harding","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2026090709460745700_oyag321-B53","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/cncr.21047","article-title":"Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy","volume":"103","author":"Agarwal","year":"2005","journal-title":"Cancer"},{"key":"2026090709460745700_oyag321-B54","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","article-title":"The relationship between daily calcium intake and bone mineral density in men with prostate cancer","volume":"99","author":"Planas","year":"2007","journal-title":"BJU Int"},{"key":"2026090709460745700_oyag321-B55","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1177\/1535370219861910","article-title":"Dietary protein and exercise for preservation of lean mass and perspectives on type 2 diabetes prevention","volume":"244","author":"de Sousa","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026090709460745700_oyag321-B56","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2026090709460745700_oyag321-B57","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/s0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2026090709460745700_oyag321-B58","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/bju.12497","article-title":"Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer","volume":"114","author":"Denham","year":"2014","journal-title":"BJU Int"},{"key":"2026090709460745700_oyag321-B59","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B60","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","article-title":"Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy","volume":"182","author":"Bhoopalam","year":"2009","journal-title":"J Urol"},{"key":"2026090709460745700_oyag321-B61","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"key":"2026090709460745700_oyag321-B62","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"2026090709460745700_oyag321-B63","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"key":"2026090709460745700_oyag321-B64","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"2026090709460745700_oyag321-B65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/s1470-2045(18)30757-5","article-title":"Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026090709460745700_oyag321-B66","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/jco.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026090709460745700_oyag321-B67","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2026090709460745700_oyag321-B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20530","article-title":"TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer","volume":"20","author":"James","year":"2016","journal-title":"Health Technol Assess"},{"key":"2026090709460745700_oyag321-B69","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"2026090709460745700_oyag321-B71","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"2026090709460745700_oyag321-B72","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"2026090709460745700_oyag321-B73","doi-asserted-by":"publisher","first-page":"1133828","DOI":"10.3389\/fonc.2023.1133828","article-title":"Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"2026090709460745700_oyag321-B74","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/2278-330x.119895","article-title":"Denosumab: a comprehensive review","volume":"2","author":"Narayanan","year":"2013","journal-title":"South Asian J Cancer"},{"key":"2026090709460745700_oyag321-B75","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"2026090709460745700_oyag321-B76","author":"Amgen Inc. Prolia","year":"2025"},{"key":"2026090709460745700_oyag321-B77","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"key":"2026090709460745700_oyag321-B78","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2026090709460745700_oyag321-B79","doi-asserted-by":"publisher","first-page":"100341","DOI":"10.1016\/j.jbo.2020.100341","article-title":"Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-na\u00efve mCRPC patients after ADT failure: a prospective analysis of the Italian real-world study ABITUDE","volume":"26","author":"Santini","year":"2021","journal-title":"J Bone Oncol"},{"key":"2026090709460745700_oyag321-B80","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/cia.S115472","article-title":"A concise review of testosterone and bone health","volume":"11","author":"Mohamad","year":"2016","journal-title":"Clin Interv Aging"},{"key":"2026090709460745700_oyag321-B81","author":"Janssen Biotech Inc","year":"2024"},{"key":"2026090709460745700_oyag321-B82","author":"Astellas Pharma UK Inc. Xtandi. Prescribing Information","year":"2025"},{"key":"2026090709460745700_oyag321-B83","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.21037\/tau.2019.05.02","article-title":"Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale","volume":"8","author":"Sedhom","year":"2019","journal-title":"Transl Androl Urol"},{"key":"2026090709460745700_oyag321-B84","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1200\/JCO.2019.37.7_suppl.237","article-title":"Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials","volume":"37","author":"Tombal","year":"2019","journal-title":"JCO"},{"key":"2026090709460745700_oyag321-B85","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.2025.43.5_suppl.81","article-title":"Effectiveness and safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC): a systematic literature review of 48 real-world studies","volume":"43","author":"Lunan","year":"2025","journal-title":"JCO"},{"key":"2026090709460745700_oyag321-B86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"2026090709460745700_oyag321-B87","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","article-title":"The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone","volume":"139","author":"Hussain","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026090709460745700_oyag321-B88","author":"FDA (Food and Drug Administration)","year":"2018","journal-title":"Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry"},{"key":"2026090709460745700_oyag321-B89","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.annonc.2026.02.009","article-title":"Final overall survival results from EORTC 1333\/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer","volume":"37","author":"Gillessen","year":"2026","journal-title":"Ann Oncol"},{"key":"2026090709460745700_oyag321-B90","author":"Saad"},{"key":"2026090709460745700_oyag321-B91","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/jbmr.4793","article-title":"Performance of FRAX in men with prostate cancer: a registry-based cohort study","volume":"38","author":"Ye","year":"2023","journal-title":"J Bone Miner Res"},{"key":"2026090709460745700_oyag321-B92","doi-asserted-by":"publisher","first-page":"e000652","DOI":"10.1136\/esmoopen-2019-000652","article-title":"Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion","volume":"5","author":"Santini","year":"2020","journal-title":"ESMO Open"},{"key":"2026090709460745700_oyag321-B93","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s00774-022-01328-4","article-title":"Assessment of bone health in patients with prostate cancer using cancer staging computed tomography","volume":"40","author":"Sato","year":"2022","journal-title":"J Bone Miner Metab"},{"key":"2026090709460745700_oyag321-B94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"2026090709460745700_oyag321-B95","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026090709460745700_oyag321-B96","doi-asserted-by":"publisher","first-page":"e2443879","DOI":"10.1001\/jamanetworkopen.2024.43879","article-title":"What to do when denosumab is stopped?","volume":"7","author":"Watts","year":"2024","journal-title":"JAMA Network Open"},{"key":"2026090709460745700_oyag321-B97","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"2026090709460745700_oyag321-B98","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"2026090709460745700_oyag321-B99","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-020-05556-0","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026090709460745700_oyag321-B100","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/jco.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026090709460745700_oyag321-B101","doi-asserted-by":"publisher","first-page":"e043","DOI":"10.5001\/omj.2013.42","article-title":"Symptomatic hypocalcemia associated with zoledronic acid treatment for osteoporosis: a case report","volume":"28","author":"Al Elq","year":"2013","journal-title":"Oman Med J"},{"key":"2026090709460745700_oyag321-B102","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s43441-024-00712-8","article-title":"Hypocalcemia event associated with denosumab: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"59","author":"Gao","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2026090709460745700_oyag321-B103","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"2026090709460745700_oyag321-B104","author":"FDA (Food and Drug Administration)","year":"2024"},{"key":"2026090709460745700_oyag321-B105","author":"FDA (Food and Drug Administration)","year":"2024"},{"key":"2026090709460745700_oyag321-B106","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.clgc.2014.11.008","article-title":"Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians","volume":"13","author":"Autio","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"2026090709460745700_oyag321-B107","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2026090709460745700_oyag321-B108","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026090709460745700_oyag321-B109","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","article-title":"Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease","volume":"93","author":"Berruti","year":"2005","journal-title":"Br J Cancer"},{"key":"2026090709460745700_oyag321-B110","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12032-022-01739-3","article-title":"Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice","volume":"39","author":"Roviello","year":"2022","journal-title":"Med Oncol"},{"key":"2026090709460745700_oyag321-B111","doi-asserted-by":"publisher","first-page":"e17100","DOI":"10.1200\/JCO.2026.44.16_suppl.e17100","article-title":"Does BMA improve outcomes in mHSPC with bone metastases?: landmark propensity-matched analysis and nested zoledronic acid vs denosumab","volume":"44","author":"Zhang","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026090709460745700_oyag321-B112","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.3390\/cancers14174305","article-title":"Bone health management in the continuum of prostate cancer disease","volume":"14","author":"Boopathi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026090709460745700_oyag321-B113","doi-asserted-by":"publisher","first-page":"159","DOI":"10.21037\/apm.2018.10.04","article-title":"External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SRES)","volume":"8","author":"Shulman","year":"2019","journal-title":"Ann Palliat Med"},{"key":"2026090709460745700_oyag321-B114","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","article-title":"Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial","volume":"42","author":"Gillespie","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag321\/70784384\/oyag321.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag321\/70784384\/oyag321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag321\/70784384\/oyag321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:46:18Z","timestamp":1788788778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag321\/8770369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":114,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag321","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag321"}}